Adding antiandrogen therapy to radiotherapy as a salvage treatment for men with biochemical recurrence following prostatectomy improves outcomes. It extends overall survival (OS) and reduces the ...

The addition of 24 months of antiandrogen therapy with bicalutamide to radiation therapy improved OS among patients with prostate cancer who have evidence of disease recurrence following radical ...

A nearly two-decades-long clinical trial has demonstrated that adding antiandrogen therapy to radiation therapy can improve the survival of prostate cancer patients who have evidence of disease ...

If treatment with a nonsteroidal antiandrogen is discontinued, appropriate alternative therapeutic approaches (e.g. medical or surgical castration) should be considered depending on the needs of ...

Antiandrogen therapy with daily bicalutamide to salvage radiation therapy resulted in significantly higher rates of long-term overall survival. Menu SECTIONS News ...

Antiandrogen withdrawal (AAWD) results in a prostate-specific antigen (PSA) response (decline in PSA level of ≥ 50%) in 15% to 30% of androgen-independent prostate cancer (AiPCa) patients. Thereafter, ...

Adding 2 years of antiandrogen therapy to salvage radiation may harm men with low PSA after radical prostatectomy (RP), according to new research presented at the 61st Annual Meeting of the ...

A protein that confers a worse prognosis in bladder cancer when present in high levels may be regulated by androgens, suggesting a role for antiandrogen agents in the treatment of this disease ...

The antiandrogen withdrawal syndrome (AAWS) is characterized by tumour regression on treatment discontinuation. Here, the mechanisms of AAWS and the development of treatment resistance are ...

Cyproterone acetate, a synthetic progestogen with antiandrogen effects, is currently approved in most European countries but not in the U.S. Across Europe, the drug has varying indications ...